Biomarkers in Giant Cells Arteritis

Study Overview
=================
Brief Summary
-----------------
Giant cells arteritis or Horton disease is a vasculitis that affects great vessels. This is the most frequent vasculitis of the population over the age of 50. This vasculitis is at the origin of an inflammatory infiltrate of arterial tunics, essentially composed of lymphocytes. Clinical signs are a deterioration of general state, unusual cephalgias, jaw pain, scalp hyperesthesia, but can also be serious ischemic complication, especially ophthalmologic with the possibility to go blind. Until now, the standard treatment is a high dosage corticosteroid therapy. Diagnosis is based on criterias of the American College of Rheumatology, dating back to 1990. The relapse rate is important, ranging from 10 to 64 % according to studies. There are also issues of becoming dependent on steroid. So it is important to determine new diagnosis markers and a therapeutic following of giant cells arteritis. With this study several biomarkers of inflammation will be studied in order to determine if one ore many of them have a good sensitivity and special feature for diagnosis and following of giant cells arteritis. The main goal is to determine a new diagnosis marker for giant cells arteritis.

Official Title
-----------------
Biomarkers in Giant Cells Arteritis

Conditions
-----------------
Giant Cells Arteritis

Intervention / Treatment
-----------------
* Behavioral: Clinical evaluation
* Other: Paraclinical evaluation
* Device: Imaging
* Other: Ophthalmologic examination
* Biological: Dosage of biomarkers


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient suffering from giant cells arteritis. Inclusion while discovery of symptoms, or during relapse. Exclusion Criteria: Healthy volunteer Treatment with corticosteroid since more than 8 days for a patient suffering from giant cells arteritis, exept for patients under corticosteroid for a polymyalgia rheumatica. Other diseases than giant cells arteritis that could introduce an inflammatory symptom, especially a tumoral process in progress or a chronic inflammatory disease (any other one than giant cells arteritis)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patient with giant gells arteritis<br>50 patients with giant gells arteritis | Behavioral: Clinical evaluation<br>* With questionnaire.<br>Other: Paraclinical evaluation<br>* Symptom inflammatory, biomarkers.<br>Device: Imaging<br>* Thoraco-abdominal scanner injected or PET scanner if contraindication for scanner.<br>Other: Ophthalmologic examination<br> <br> |
| Other: Control patients<br>50 control patients : blood from French national blood service (EFS) | Biological: Dosage of biomarkers<br>* Control patients.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biomarkers's serum sampling | For dosage of biomarkers in serum, like serum amyloid A or interleukins. | 3 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arteritis, Biomarker, Horton disease